Emergent BioSolutions Inc (NYSE:EBS), through its subsidiary Emergent Manufacturing Operations Baltimore, has reached a settlement with Janssen Pharmaceuticals, Inc., a branch of Johnson & Johnson (NYSE:JNJ), resolving disputes related to the manufacturing of Johnson & Johnson’s investigational COVID-19 vaccine. This settlement ends claims arising from their manufacturing services agreement and related arbitration. Related: Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday? Under the confidential Settlement Agreement and Release terms, ...